PubRank
Search
About
Neil Wintfeld
Author PubWeight™ 16.09
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Pharmacoeconomics
2004
1.68
2
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a.
Liver Int
2008
1.56
3
The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
J Hepatol
2004
1.22
4
Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.
Semin Arthritis Rheum
2010
1.15
5
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
Pharmacoeconomics
2003
1.05
6
The association of body mass index with the risk of type 2 diabetes: a case-control study nested in an electronic health records system in the United States.
Diabetol Metab Syndr
2014
1.04
7
Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status.
Pharmacoeconomics
2015
1.02
8
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
J Gastroenterol Hepatol
2006
0.94
9
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Support Care Cancer
2008
0.89
10
Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen.
J Acquir Immune Defic Syndr
2004
0.85
11
Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy.
J Med Econ
2012
0.83
12
Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.
AIDS Res Hum Retroviruses
2006
0.82
13
Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
J Cancer Res Ther
2010
0.81
14
Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy.
HIV Clin Trials
2005
0.81
15
Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks.
HIV Clin Trials
2003
0.80
16
Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication.
HIV Clin Trials
2002
0.77